Cancer-Cell-Specific Nuclear-Targeted Drug Delivery by Dual-Ligand-Modified Mesoporous Silica Nanoparticles

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery Systems

Background:

• Mesoporous silica nanoparticles (MSNs) offer versatile platforms for drug delivery.
• Targeted delivery systems are crucial for enhancing therapeutic efficacy and minimizing off-target toxicity in cancer treatment.
• Developing cancer-cell-specific delivery systems requires precise targeting strategies.

Purpose of the Study:

• To engineer a novel nuclear-targeted delivery system using mesoporous silica nanoparticles.
• To functionalize MSNs with dual targeting ligands, folic acid and dexamethasone, for cancer cell specificity.
• To evaluate the enhanced efficacy and reduced toxicity of doxorubicin delivered via the targeted MSNs.

Main Methods:

• Modification of mesoporous silica nanoparticles with folic acid and dexamethasone.
• Construction of a dual-ligand targeted nanocarrier system.
• Assessment of doxorubicin inhibition efficacy on Hela cells.
• Evaluation of selective cellular uptake and toxicity in non-cancer cells.

Main Results:

• The dual-ligand modified MSNs demonstrated enhanced doxorubicin inhibition efficacy on Hela cells.
• Active nucleus accumulation of doxorubicin was observed in cancer cells.
• Receptor-mediated selective cellular uptake reduced toxic side effects on non-cancer cells.

Conclusions:

• Dual-ligand functionalized MSNs serve as an effective cancer-cell-specific nuclear-targeted delivery system.
• This targeted approach enhances the therapeutic index of doxorubicin by improving cancer cell targeting and reducing systemic toxicity.
• The developed nanocarrier system holds promise for improved cancer chemotherapy.